IQVIA Holdings Inc. — 2019 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2019; the fourth-quarter figures below are unaudited. IQVIA provides analytics, healthcare data and technology, clinical research, and contract sales and medical services. It operates globally through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Financial performance
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $11.088 billion | $10.412 billion |
| Operating income | $777 million | $741 million |
| Net income attributable to IQVIA | $191 million | $259 million |
| Diluted EPS | $0.96 | $1.24 |
| Cash from operating activities | $1.417 billion | $1.254 billion |
| Capital expenditures | $582 million | $459 million |
| Cash and cash equivalents at year-end | $837 million | $891 million |
| Total debt at year-end | $11.705 billion | $11.056 billion |
- Revenue grew 6.5% reported, or approximately 8.0% in constant currency; currency movements reduced reported growth by about $159 million.
- Operating margin was approximately 7.0%, compared with 7.1% in 2018. Costs of revenue were 65.8% of revenue versus 64.8%; SG&A declined to 15.6% from 16.5% of revenue.
- Operating cash flow less capital expenditures was approximately $835 million, up from $795 million. Investing activities used $1.190 billion, including $588 million net cash paid for acquisitions.
- Current assets were $4.126 billion and current liabilities $3.945 billion. The company reported $1.131 billion available under its revolving credit facility; no additional revolving loans were available under its receivables facility.
Fourth-quarter results
Revenue was $2.895 billion, compared with $2.688 billion in Q4 2018. Operating income was $166 million versus $207 million; net income attributable to IQVIA was $16 million versus $69 million, and diluted EPS was $0.09 versus $0.34.
Material changes and segment trends
- Technology & Analytics Solutions revenue rose 8.4% to $4.486 billion; segment profit increased 5.8% to $1.101 billion.
- Research & Development Solutions revenue increased 5.9% to $5.788 billion; segment profit rose 8.2% to $1.141 billion. Contracted backlog grew to $19.0 billion from $17.1 billion, with approximately $5.2 billion expected to convert to revenue in the next 12 months. Management cautions that backlog is not a consistent predictor of revenue.
- Contract Sales & Medical Solutions revenue was nearly flat at $814 million; segment profit fell 14.8% to $52 million.
- Net income attributable to IQVIA declined despite revenue and operating-income growth. Higher interest expense, increased income tax expense, and lower equity-method earnings contributed to the year-over-year earnings decline. The effective tax rate was 33.0%, versus 18.0% in 2018; 2019 included a $25 million expense reversing a previously recorded FDII tax benefit.
Outlook, risks and unusual items
- The filing provides no specific company revenue or earnings guidance. Management stated that cash, expected operating cash flows, and access to revolving and receivables facilities were expected to fund operations, capital expenditures, and debt obligations for at least 12 months.
- Management identifies demand drivers including life-sciences R&D and outsourcing, demand for real-world evidence, healthcare data integration, and pressure on clients to improve efficiency. These are market views, not a quantified IQVIA forecast.
- Key risks include short-notice contract termination or delay, backlog conversion and project-cost estimates, reliance on third-party data suppliers, privacy and data-security regulation, cyber incidents, clinical-trial execution and liability, foreign exchange, acquisitions and integration, and competition.
- IQVIA had $11.705 billion of debt, including variable-rate borrowings; debt agreements impose financial and operational covenants and substantially secure certain facilities. The company reported covenant compliance in all material respects at year-end. It also flagged potential LIBOR transition and interest-rate exposure.
- Restructuring charges were $75 million in 2019, with further actions expected during 2020. The company issued $1.1 billion of 5.00% senior notes due 2027 and €720 million of 2.25% notes due 2028, and redeemed $800 million of 4.875% notes due 2023, incurring $24 million of debt-extinguishment costs.
- Notable legal matters include an appeal in South Korea concerning privacy-law treatment of non-identified data and ongoing litigation with Veeva, including Veeva counterclaims. Management said it did not expect pending proceedings, claims, and litigation in aggregate to have a material adverse effect, while noting outcomes remain uncertain.
- The auditor issued an unqualified opinion and identified estimating costs to complete clinical-research contracts, which affects revenue recognized over time, as a critical audit matter. Management and the auditor concluded internal control over financial reporting was effective.
Investor facts to verify
- Whether revenue growth and R&D backlog convert into sustained segment profit and cash generation, particularly given weaker Q4 earnings and Contract Sales & Medical Solutions trends.
- Debt maturities, interest costs, variable-rate exposure, covenant headroom, and refinancing needs.
- Cash conversion and working-capital movements, including growth in unbilled services and the timing of clinical-trial milestone billings.
- Tax-rate assumptions and resolution of FDII guidance, tax audits, and uncertain tax positions.
- Developments in the South Korean privacy and Veeva matters, and the company’s ability to maintain compliant, secure access to third-party healthcare data.